0
0
Recent research from Switzerland and wider Europe has challenged the long-held assumption that most migrants diagnosed with HIV acquired the infection prior to migration. Instead, new evidence shows a significant proportion of migrants acquire HIV after arriving in Europe, underscoring the urgent need for tailored HIV prevention, testing, and early treatment efforts within migrant populations.
Shifting Epidemiology:
A 15-year analysis from the Swiss HIV Cohort Study (SHCS), involving 3,490 participants between 2010 and 2024, revealed 62.1% of migrant HIV diagnoses occurred post-migration, contradicting earlier assumptions that migrants primarily arrive already infected. Men who have sex with men (MSM) accounted for the highest share (43.1%) of post-migration infections, followed by female heterosexuals (27.2%) and male heterosexuals (18.9%).
These late diagnoses were frequently accompanied by more advanced immune suppression, indicating delays in testing and diagnosis among migrants compared to Swiss nationals. The median time from migration to diagnosis varied, with male heterosexual migrants showing the longest interval at six years, suggesting ongoing transmission risks and barriers to early detection.
Europe-wide data mirror this trend. In 2023, migrants accounted for nearly half of new HIV diagnoses in the European Union and European Economic Area (EU/EEA), with an estimated 30% of infections acquired post-migration, varying notably by country and population subgroup. Migrants face intersecting challenges including cultural, social, and legal barriers that hinder access to HIV prevention and care services.
Expert Insights on Implications and Challenges
Dr. Julia Duran Ramirez, lead author of the Swiss cohort analysis, emphasized, “Understanding whether infections occur post-migration is crucial to developing effective prevention and testing programs that address the specific needs of migrant communities.” She noted that delayed diagnoses undermine treatment outcomes and increase transmission risks within and beyond migrant groups.
Independent infectious disease specialists highlight that migrants often experience structural vulnerabilities such as limited healthcare access, language barriers, stigma, and discrimination. These factors contribute not only to later HIV diagnosis but also to increased risk of treatment interruption and poor clinical outcomes. A systematic review published in The Lancet HIV confirms that migrants in Europe have higher rates of progression to AIDS and loss to follow-up compared to non-migrants.
Context and Background: Migrant Vulnerability and HIV Prevention Gaps
Historically, HIV prevention efforts targeted migrants mainly at entry points, aiming to identify infections prior to or shortly after arrival to European countries. However, the emerging evidence reveals that many migrants acquire HIV years after settling in Europe. Several reasons account for this:
-
Insufficient access to comprehensive HIV prevention tools such as pre-exposure prophylaxis (PrEP), condoms, and culturally appropriate education.
-
Social determinants including poverty, precarious legal status, and stigma that limit healthcare engagement.
-
Mobility patterns such as travel to visit friends and relatives in countries with higher HIV prevalence, creating ongoing exposure risks.
The European Centre for Disease Prevention and Control (ECDC) reports that while viral suppression rates are improving, significant gaps remain among migrants, especially those who are undocumented or marginalized. These gaps hamper Europe’s ability to meet the UNAIDS 95-95-95 targets essential for controlling the epidemic.
Public Health Implications: Priorities for Action
The evidence underscores the need for public health policies to expand beyond initial migration screening to sustained, inclusive HIV prevention and testing programs designed for migrants throughout their residency. Key priorities include:
-
Culturally sensitive outreach and education tailored to diverse migrant communities.
-
Enhanced HIV testing availability in non-traditional settings to facilitate earlier diagnosis.
-
Broader access to PrEP and linkage to care services without legal or administrative barriers.
-
Addressing stigma and discrimination through community engagement to improve health equity.
Health authorities across Europe must also consider social determinants of health and legal protections to reduce barriers that elevate HIV risk and impede care engagement among migrants.
Limitations and Conflicting Perspectives
While post-migration acquisition rates are rising, differentiating newly acquired infections from delayed diagnoses of pre-existing infections remains complex. Variability between countries and subpopulations reflects heterogeneity in epidemiological surveillance, healthcare access, and social contexts, challenging a one-size-fits-all approach.
Moreover, some experts caution that overemphasizing post-migration acquisition risks stigmatizing migrants further, potentially reinforcing misconceptions about transmission dynamics. Balanced reporting must therefore recognize that migrants’ HIV risks are shaped by a combination of pre- and post-migration factors and broader structural conditions.
What This Means for Readers
For readers, this analysis highlights the importance of regular HIV testing and preventive measures regardless of migration status or duration of stay in Europe. It also emphasizes that access to culturally competent healthcare and removing barriers to prevention and treatment services are paramount for controlling HIV in diverse communities.
Healthcare providers should be aware of these epidemiological shifts to ensure early diagnosis and linkage to care among migrant patients. For migrants and their communities, informed engagement with HIV prevention tools such as PrEP, condoms, and routine testing is crucial to personal and public health.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
